Revive Therapeutics Ltd (TSE:RVV)
:RVV
RVV Stock Chart & Stats
C$0.01
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.01
C$0.00(0.00%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.08
Previous CloseN/A
Volume2.50K
Average Volume (3M)285.50K
Market Cap
C$14.65M
Enterprise ValueC$17.47M
Total Cash (Recent Filing)C$30.95K
Total Debt (Recent Filing)C$68.18K
Price to Earnings (P/E)―
Beta-1.05
Next Earnings
May 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding418,564,270
10 Day Avg. Volume295,136
30 Day Avg. Volume285,498
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.43
Price to Sales (P/S)0.00
P/FCF Ratio-10.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Asset-light, Partnership-ready Business ModelRevive’s business model centers on developing drug candidates to monetize via partnerships, licensing, or selective commercialization. That asset-light pathway is durable: it allows de-risking through partners, limits upfront commercialization capex, and preserves strategic optionality over months to years.
Low Absolute Debt BurdenWith very modest reported debt in absolute dollars, the company faces lower fixed financial obligations. This reduces near-term insolvency risk and gives flexibility in choosing financing routes (equity, partnerships) to fund trials — a durable structural strength while pre-revenue.
Improving Loss Trend Versus Recent YearReported net losses have narrowed versus FY2024, indicating improving cost control or scaled-down outlays. That trend extends the runway and suggests management is lowering burn, a sustainable operational improvement that can materially affect financing needs over the next several quarters.
Bears Say
No Operating RevenueThe company remains pre-revenue, meaning all value hinges on successful clinical progress, approvals, or deals. Lacking product sales creates persistent dependency on external financing or partners, which is a structural risk to sustaining R&D and advancing programs over 2–6 months and beyond.
Negative Shareholders' Equity And Weakened Balance SheetNegative equity and a marked drop in total assets materially reduce financial resilience. This weaker balance sheet limits borrowing capacity, raises counterparty concerns, and increases reliance on dilutive financing or partnerships to fund operations — a lasting constraint on strategic flexibility.
Persistent Cash Burn; Not Self-fundingOngoing negative operating and free cash flow means the company cannot self-fund development. Even modest but persistent burn requires periodic capital raises or deal-making, which can dilute shareholders and complicate long-term program continuity if financing markets or partner interest weaken.
Revive Therapeutics News
RVV FAQ
What was Revive Therapeutics Ltd’s price range in the past 12 months?
Revive Therapeutics Ltd lowest stock price was <C$0.01 and its highest was C$0.08 in the past 12 months.
What is Revive Therapeutics Ltd’s market cap?
Revive Therapeutics Ltd’s market cap is C$14.65M.
When is Revive Therapeutics Ltd’s upcoming earnings report date?
Revive Therapeutics Ltd’s upcoming earnings report date is May 29, 2026 which is in 51 days.
How were Revive Therapeutics Ltd’s earnings last quarter?
Revive Therapeutics Ltd released its earnings results on Feb 27, 2026. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.
Is Revive Therapeutics Ltd overvalued?
According to Wall Street analysts Revive Therapeutics Ltd’s price is currently Overvalued.
Does Revive Therapeutics Ltd pay dividends?
Revive Therapeutics Ltd does not currently pay dividends.
What is Revive Therapeutics Ltd’s EPS estimate?
Revive Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Revive Therapeutics Ltd have?
Revive Therapeutics Ltd has 418,564,270 shares outstanding.
What happened to Revive Therapeutics Ltd’s price movement after its last earnings report?
Revive Therapeutics Ltd reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 50%.
Which hedge fund is a major shareholder of Revive Therapeutics Ltd?
Currently, no hedge funds are holding shares in TSE:RVV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Technical Analysis
Options Prices
Currently, No data available
---